A prospective study of dextran-induced anaphylactoid reactions (DIAR) in 5745 gynaecological and obstetric patients who received dextran 70 solution intravenously while undergoing major surgery revealed 8 patients who had Grade I or Il reactions and 7 patients who had Grade III or IV reactions. The incidence of severe reactions was 1:821 patients treated. The overall incidence of reactions per patient treated was 1:383. One neonatal death followed a dextran-induced cardiac arrest in a woman about to undergo caesarean section. The risks of dextran 70 treatment exceeded the risks of thromboembolism in these patients.
Dextran solutions are among the most widely used colloid plasma volume expanders in the world. They were first used for this purpose in 1947 and the early history of this has been documented by Thorsen. I The anaphylactoid reaction inducing potential of dextran appears to be a function of both molecular size and branching frequency, with the anaphylactoid potential increasing as molecular size and branch numbers increase. 2 That severe reactions could occur was recognised soon after its introduction. Early workers attributed this to the antigenicity of dextran or to contamination of the dextran by bacterial endotoxin. 3 Changes in manufacturing processes have reduced the endotoxin content and also resulted in much tighter control of the molecular weight distribution of the dextran solutions.
Despite these efforts severe reactions still occur and Ring4 reviewing 208 DIARs in Germany reported a 15070 incidence of cardiac arrest in those patients. Dextran solutions have long been regarded as useful in volume replacement because of their relatively long half life, when compared to crystalloids, and for their antithrombotic effect, believed to result from a combination of haemodilution, reduction of blood viscosity and a specific effect on platelet adhesiveness.
Because pregnant women are in a relatively hypercoagulable state and may be confined to bed after caesarean section dextran 70 has been used in this department as an antithrombotic at caesarean section for the last 10 to 15 years. Similarly it was believed that women undergoing major pelvic surgery were at increased risk of thromboembolism and they also were given dextran solutions intra and postoperatively. 5 Comments by anaesthetists that DIARs seemed to be relatively frequent led to this study.
METHODS
Dextran 70 solutions were administered intravenously to patients undergoing major gynaecological surgery or caesarean section. The indications included volume expansion during epidural anaesthesia, replacement of blood volume lost during surgery and thrombosis prophylaxis. The prescription of the dextran was left to the discretion of the anaesthetist. Dextran solutions were not administered to patients with a past history of dextran allergy, atopy or drug allergy. In general, patients received one litre of dextran 70 solution in the first 24 hours and half a litre per 24 hours subsequently until the intravenous cannula was removed. Dextran 70 in dextrose (Macrodex in dextrose, Pharmacia) was used in 670/0 of cases and the remainder received dextran 70 in saline (Macrodex in saline, Pharmacia).
Over a period of 63 months from January 1981 to March 1986 the use of dextran was monitored through pharmacy records and its use for individual patients was noted on the anaesthetic record. Any reactions which occurred were recorded on an appropriate form and classified according to the modified criteria of Ring and Messmer. 6, 7 The classification of the reactions is summarised in Table 1 . Severe reactions were treated with cessation of dextran administration and by giving oxygen, adrenaline, intravenous fluids and when appropriate, cardiopulmonary resuscitation.
All patients who received other drugs, prior to the administration of dextran, were subsequently skin tested according to the method of Fishers and were shown to be nonreactors to those drugs.
RESULTS
During the period of the study 15,361 patients underwent major surgery and of these 5745 (37.4%) received a total of 12,646 half litre units of dextran 70. The average number of dextran units transfused was 2.2 per patient.
Fifteen reactions were recorded (see Table 2 ), a rate of one reaction per 383 patients treated or 0.26%. Seven of these reactions were potentially life-threatening Grade III or IV reactions giving a combined incidence of such reactions of 1:821 patients treated (0.12%). The remaining eight reactions were less severe Grade I or 11 reactions and the combined incidence of such reactions was 1 :718 patients treated (0.14%). The anaphylactoid response in each case appeared within a maximum of 5 minutes after the commencement of the administration of the dextran solution. In Table 3 the frequency of the different grades of reactions is summarised.
One neonatal death resulted indirectly from a Grade IV reaction in a woman who had been given an epidural anaesthetic prior to undergoing caesarean section. She suffered a cardiac arrest within minutes of being given 20-30 ml of dextran 70 solution. Despite prompt and vigorous cardiopulmonary resuscitation and the administration of adrenaline, oxygen, additional intravenous fluids and the use of lateral tilt she had a systolic blood pressure of 60 mmHg for about 10 minutes. The baby was delivered by caesarean section about 20 minutes after the onset of DIAR but showed signs of severe hypoxic brain damage and died seven weeks later.
suffered cardiac arrest after small volumes of dextran 70 solutions were infused. One patient was having a general anaesthetic and responded rapidly to cardiopulmonary resuscitation, adrenaline and fluid therapy and made a rapid Two other patients undergoing hysterectomy 1. PAULL recovery. The second patient was under epidural anaesthesia and light sedation with thiopentone and diazepam. She responded slowly and required an adrenaline infusion for 2 hours before being able to sustain a low normal blood pressure.
DISCUSSION
The administration of any treatment to a patient carries risks and can only be justified if the benefits accruing significantly outweigh those risks. Plasma volume expanders are no exception to this principle and Isbister and Fisher 9 have highlighted the adverse effects of these substances. In this case the risks of treatment which can be identified and quantified are relatively frequent and serious in their implications.
Anaesthetists possibly use dextran solutions more frequently than any other practitioners. In 1983-84 five cases of severe but non-fatal dextran reaction were reported by anaesthetists to the Victorian Consultative Council on Anaesthetic Mortality and Morbidity. 10 Ring reported that the frequency of systemic anaphylactoid reaction to colloid infusions, calculated per patient treated, varied from 0.1070 to 1.0%.11 In this series it was 0.12%. Many anaesthetists have commented that there appears to be an increase in the frequency and severity of reactions to dextran 70. This study provides no evidence to support that belief but with a frequency of 1 reaction in each 383 patients treated it would not be surprising if most anaesthetists who used dextran 70 had experienced a reaction in one of their own patients or had assisted one of their colleagues to manage such a patient.
In women undergoing major or radical gynaecological surgery the frequency of deep vein thrombosis was shown by Crandon and Koutts to be of the order of 38%.5 In other series gynaecological patients have been shown to have deep vein thrombosis in 10 to 19% of cases. 12. 13 The frequency of thromboembolism, which this treatment is attempting to minimise, was not investigated in this group of patients. However, it is known that none of the 15,361 patients undergoing major surgery during this period died from pulmonary embolism despite the fact that more than two-thirds of them did not receive the dextran prophylaxis. This must be contrasted with the three cardiac arrests which followed dextran 70 administration and one neonatal death which resulted from a maternal cardiac arrest.
In Victoria the only large group of patients in which the frequency of death from fatal pulmonary embolism can be determined with reasonable accuracy is women undergoing childbirth. Reports of maternal deaths over a similar period indicate that the death rate from pulmonary embolism is of the order of 1: 180,000 births. 14 -19 This suggests that if dextran were to be given to all pregnant women the frequency of cardiac arrest or major circulatory collapse would be some 220 times greater than the frequency of death from pulmonary embolism. On this basis the use of dextran 70 as a routine prophylaxis against thromboembolism in caesarean section is impossible to justify.
It seems likely that environmental factors influence the frequency of DIARs in any given community. Dextran is a component of toothpaste, sucrose, sucrose-containing foods and some prescribed medications and many individuals can be shown to carry dextranreactive antibodies. 2o , 21 Hedin and Richter showed that patients who react to dextran tend to have higher levels of dextran-reactive antibodies than do nonreactors. 22 Hedin, Richter and Ring showed that the pre-exposure levels of dextran-reactive antibodies correlated directly with the severity of the subsequent DIARY The relatively high incidence of reactions in the patients in the present study may be related to the known high sucrose consumption in Australia. Other factors, known to be related to the occurrence and severity of DIAR include atopy and a history of chronic inflammation, particularly inflammatory bowel disease. Patients with atopy tend to suffer Grade I and 11 reactions and patients with chronic inflammatory disease tend to have Grade III and IV reactions."
The use of haptens to decrease the frequency and severity of DIAR seems to have some application though a fatal reaction to hapten has been reported. 24 The use of hapten may lower the frequency of severe DIAR in this community to the point where the use of dextran can be justified for those patients who have an increased risk of thromboembolism, for example patients with cancer or those with a past history of thromboembolic disease.
The findings in this study suggest that a patient undergoing caesarean section or major gynaecological surgery faces greater risk from dextran-induced anaphylactoid reaction than from pulmonary embolism. The place of dextran in the routine prophylaxis of thromboembolic disease in those patients undergoing major gynaecological or obstetric surgery must be questioned.
